


$$\begin{array}{c}
 \text{O} \\
 \parallel \\
 * - \text{C} - \text{O} - \text{R}^7
 \end{array}
 \quad
 \begin{array}{c}
 \text{O} \quad \text{O} \\
 \parallel \quad \parallel \\
 * - \text{C} - \text{N}(\text{R}^9) - \text{C} - \text{O} - \text{R}^7
 \end{array}
 \quad
 \begin{array}{c}
 \text{O} \\
 \parallel \\
 * - \text{C} - \text{N}(\text{R}^9) - \text{R}^7
 \end{array}
 \quad
 \begin{array}{c}
 \text{O} \\
 \parallel \\
 * - \text{C} - \text{N}(\text{R}^9) - \text{R}^8
 \end{array}
 \quad
 \begin{array}{c}
 \text{O} \quad \text{R}^9 \\
 \parallel \quad | \\
 * - \text{C} - \text{O} - (\text{C})_q - \text{H} - \text{W}^3 \\
 \quad \quad | \\
 \quad \quad \text{R}^7
 \end{array}$$

- 10 where **q** is 1, 2, or 3, **W**³ is —O—; —N(R⁹)—; or —OC(=O)—; **R**⁷ is selected from —H—; —(C₁–C₆) alkyl, —(C₂–C₆) alkenyl, or —(C₂–C₆) alkynyl substituted by 0 to 3 substituents R¹⁰; —(CH₂)_u–(C₃–C₇) cycloalkyl where u is 0, 1 or 2, substituted by 0 to 3 R¹⁰; and phenyl or benzyl substituted by 0 to 3 R¹⁴; **R**⁸ is tetrazol-5-yl; 1,2,4-triazol-3-yl; 1,2,4-triazol-3-on-5-yl; 1,2,3-triazol-5-yl; imidazol-2-yl; imidazol-4-yl; imidazolidin-2-on-4-yl; 1,3,4-oxadiazolyl; 1,3,4-oxadiazol-2-on-5-yl; 1,2,4-oxadiazol-3-yl; 1,2,4-oxadiazol-5-on-3-yl; 1,2,4-oxadiazol-5-yl; 1,2,4-oxadiazol-3-on-5-yl; 1,2,5-thiadiazolyl; 1,3,4-thiadiazolyl; morpholinyl; parathiazinyl; oxazolyl; isoxazolyl; thiazolyl; isothiazolyl; pyrrolyl; pyrazolyl; succinimidyl; glutarimidyl; pyrrolidonyl; 2-piperidonyl; 2-pyridonyl; 4-pyridonyl; pyridazin-3-onyl; pyridyl; pyrimidinyl; pyrazinyl; pyridazinyl; indolyl; indolinyl; isoindolinyl; benzo[b]furanyl; 2,3-dihydrobenzofuranyl; 1,3-dihydroisobenzofuranyl; 2*H*-1-benzopyranyl; 2-*H*-chromenyl; chromanyl; benzothieryl; 1*H*-indazolyl; benzimidazolyl; benzoxazolyl; benzisoxazolyl; benzothiazolyl; benzotriazolyl; benzotriazinyl; phthalazinyl; 1,8-naphthyridinyl; quinolinyl; isoquinolinyl; quinazolinyl; quinoxalinyl; pyrazolo[3,4-*d*]pyrimidinyl; pyrimido[4,5-*d*]pyrimidinyl; imidazo[1,2-*a*]pyridinyl; pyridopyridinyl; pteridinyl; or 1*H*-purinyl; or **A** is selected from phosphorous and sulfur acid groups; **W** is —O—; —S(=O)_t—, where t is 0, 1, or 2; or —N(R³)—; **Y** is =C(R^{1a})—, or
- 25

- 5 $-\text{[N}\Rightarrow(\text{O})_k]$ where k is 0 or 1; R^4 , R^5 and R^6 are (1) $-\text{H}$; provided that R^5 and R^6 are not both $-\text{H}$ at the same time, $-\text{F}$; $-\text{Cl}$; $-(\text{C}_2-\text{C}_4)$ alkynyl; $-\text{R}^{16}$; $-\text{OR}^{16}$; $-\text{S}(=\text{O})_p\text{R}^{16}$; $-\text{C}(=\text{O})\text{R}^{16}$; $-\text{C}(=\text{O})\text{OR}^{16}$; $-\text{OC}(=\text{O})\text{R}^{16}$; $-\text{CN}$; $-\text{NO}_2$; $-\text{C}(=\text{O})\text{NR}^{16}\text{R}^{17}$; $-\text{OC}(=\text{O})\text{NR}^{16}\text{R}^{17}$; $-\text{NR}^{12}_a\text{C}(=\text{O})\text{NR}^{16}\text{R}^{17}$; $-\text{NR}^{12}_a\text{C}(=\text{NR}^{12})\text{NR}^{16}\text{R}^{17}$; $-\text{NR}^{12}_a\text{C}(=\text{NCN})\text{NR}^{15}\text{R}^{16}$; $-\text{NR}^{12}_a\text{C}(=\text{N-NO}_2)\text{NR}^{15}\text{R}^{16}$; $-\text{C}(=\text{NR}^{12}_a)\text{NR}^{15}\text{R}^{16}$; $-\text{CH}_2\text{C}(=\text{NR}^{12}_a)\text{NR}^{16}\text{R}^{17}$; $-\text{OC}(=\text{NR}^{12}_a)\text{NR}^{16}\text{R}^{17}$; $-\text{OC}(=\text{N-NO}_2)\text{NR}^{16}\text{R}^{17}$; $-\text{NR}^{16}\text{R}^{17}$; $-\text{CH}_2\text{NR}^{16}\text{R}^{17}$; $-\text{NR}^{12}_a\text{C}(=\text{O})\text{R}^{16}$; $-\text{NR}^{12}_a\text{C}(=\text{O})\text{OR}^{16}$; $=\text{NOR}^{16}$; $-\text{NR}^{12}_a\text{S}(=\text{O})_p\text{R}^{17}$; $-\text{S}(=\text{O})_p\text{NR}^{16}\text{R}^{17}$; and $-\text{CH}_2\text{C}(=\text{NR}^{12}_a)\text{NR}^{16}\text{R}^{17}$; (2) $-(\text{C}_1-\text{C}_4)$ alkyl including dimethyl and $-(\text{C}_1-\text{C}_4)$ alkoxy substituted with 0 to 3 substituents $-\text{F}$ or $-\text{Cl}$; or 0 or 1 substituent (C_1-C_2) alkoxycarbonyl-, (C_1-C_2) alkylcarbonyl-, or (C_1-C_2) alkylcarbonyloxy-; or (3) an aryl or heterocyclic moiety; or (4) R^5 and R^6 are taken together to form a moiety of partial Formulas
- 10 (1.3.1) through (1.3.15):



or a pharmaceutically acceptable salt thereof.